The new effort combines adaptive platform trial design, AI-enabled site activation, nationwide data infrastructure, and patient data contribution tools to reduce timelines, costs, and patient burden across clinical development.
|Articles|October 28, 2013
Synexus Continues to Build in Eastern Europe, Opening a New Regional Center to Support Global Clinical Trials
Synexus has opened a regional office for Eastern Europe in Wroclaw, Poland. The investment reflects Synexus? continued commitment to the region and has been created to service the important role that clients see for Eastern Europe in terms of global clinical trials.
Advertisement
Synexus has opened a regional office for Eastern Europe in Wroclaw, Poland. The investment reflects Synexus’ continued commitment to the region and has been created to service the important role that clients see for Eastern Europe in terms of global clinical trials.
The new 3,000 square foot office located will house a strong regional team with experience in delivering clinical trials for Synexus clients. The extra space will allow Synexus to further strengthen this team that has over a decade of experience in Eastern Europe. The team will be responsible for Synexus’ patient engagement programs as well as the management of Synexus’ nine dedicated research centers across Poland, Hungary, Romania, Ukraine and Bulgaria.
Regional Managing Director, Dr Radoslaw Janiak commented: “Our success in the region is based on our ability to deliver patients and quality data to our clients in pharma. We have put in place a sophisticated patient engagement program which really improves the patient experience and it is these added-value extras which really pay dividends in terms of client success.”
Christophe Berthoux CEO of Synexus, who attended the opening, commented, “We have an exceptional team in Eastern Europe who have consistently met the needs of our customers. For example, it is no accident that the Wroclaw site was the first Synexus site to be selected to join Pfizer’s Inspire site network[1].”
Mayor of Wroclaw Rafał Dutkiewicz and Prof. Krzysztof Strojek, M.D., PhD , National Consultant in Diabetology opened the new facilities and addressed the guests who came from across the region including executives from top pharma, Amgen, Merck, Servier, AstraZeneca, NovoNordisk, Pfizer, and the world’s leading CROs, Covance, Inventiv, PPD and Parexel.
Synexus, which has more than 25 dedicated research centres across Europe and Africa, focuses on undertaking clinical trials in the therapy areas where it can provide most value – cardiovascular, metabolic (diabetes and obesity), bone, respiratory and CNS (dementia and pain).
[1] INSPIRE, which stands for Investigator Networks, Site Partnerships and Infrastructure for Research Excellence, means that these sites have early access to Pfizer‘s portfolio data and advanced information regarding the clinical trials to be sponsored by Pfizer. They are also involved in publications in scientific journals, protocol design, advisory boards and the sharing of best practice across the INSPIRE network.
Advertisement
Related to this article
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is shifting trial risk management from reactive to proactive—enabling sponsors to pressure-test protocols and anticipate pivots before a single patient is enrolled.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
AI agents in clinical operations acquire broader autonomous capability through expanded permissions, tools, memory, and delegated authority, requiring governance focused on whether effective capability has shifted outside approved boundaries rather than whether software has changed.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
RWE is finding a role earlier in drug development than ever before, but the data quality, integration, and organizational alignment required to make it regulatory-grade are still catching up to the ambition.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains why combining analog trial performance data with real-world patient data and site-level recruitment history gives sponsors a far more honest picture of whether their enrollment assumptions are actually achievable.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials
2
Where AI Leads in Trial Design—and Where Humans Still Need To
3
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
4
What an AI-Informed Approach Means for How Sponsors Think About Risk
5